As filed with the Securities and Exchange Commission on January 7, 2026. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 AETHLON MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 3826 13-3632859 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 11555 Sorr ...

Core Insights - West Pharmaceutical Services, Inc. (NYSE:WST) is recognized as one of the 14 Best Dividend Growth Stocks to Buy and Hold in 2026 [1] Group 1: Market Demand and Growth Drivers - KeyBanc projects that injectable GLP-1 drugs will continue to drive demand for West Pharmaceutical, with limited risk to oral weight loss drugs through 2030 [2] - The firm estimates that the oral version of Wegovy will only contribute approximately 200 basis points to the total GLP-1 market share by 2030, indicating a conservative outlook on oral drug adoption [2] - West Pharmaceutical's drug components business now accounts for 47% of total revenue, reflecting strong demand for components used in GLP-1 weight-loss and diabetes drugs [3] Group 2: Product Offerings - West Pharmaceutical supplies essential medical components such as stoppers, plungers, and delivery systems, which are critical for the safe storage and administration of injectable medicines, including vaccines and biologics [4]

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks ...

Key Takeaways BFLY plans a Beam Steering API launch, opening core imaging access to third-party developers.Software-based beam steering on a chip supports Biplane, iQ Slice and iQ Fan, simplifying image capture.After the news, BFLY shares rose 4.9%, extending a 115.9% six-month rally.Butterfly Network (BFLY) recently announced its plans to launch its Beam Steering API to support advanced third-party AI applications and technology development. The API, expected to be released in the first half of 2026, will ...

Core Insights - AngioDynamics, Inc. (ANGO) reported breakeven adjusted earnings per share for the second quarter of fiscal 2026, an improvement from a loss of 4 cents in the same quarter last year, surpassing the Zacks Consensus Estimate of a loss of 10 cents [1][2] - The company’s pro-forma revenues for the fiscal second quarter reached $79.4 million, reflecting an 8.8% year-over-year increase and exceeding the Zacks Consensus Estimate by 4.5% [3][10] - Despite the positive financial results, shares of AngioDynamics fell nearly 13.5% in the trading session following the announcement [4] Revenue Analysis - U.S. net revenues for the quarter totaled $67.6 million, up 7.8% year over year, surpassing the estimate of $62.3 million [5] - Pro-forma international revenues were $11.8 million, an 8.8% increase from the previous year, exceeding the projection of $10.2 million [5] Segment Performance - The Med Tech segment reported pro-forma net sales of $35.7 million, a 13% increase year over year, outperforming the estimate of $32.7 million [6] - Key drivers included Auryon sales of $16.3 million (up 18.6% year over year) and Mechanical Thrombectomy revenues of $11 million (up 3.9% year over year) [7] - Pro-forma Med Device revenues totaled $43.8 million, reflecting a 5.6% increase compared to the previous year, also exceeding the estimate of $39.9 million [8] Margin and Expense Analysis - AngioDynamics' pro forma gross profit rose 14% to $44.8 million, with gross margin expanding by 170 basis points to 56.4%, surpassing the projected margin of 54.2% [11][10] - Sales and marketing expenses increased by 4.4% year over year to $26.7 million, while R&D expenses rose by 20.7% to $7.8 million [12] Cash Position - The company ended the second quarter with cash and cash equivalents of $41.6 million, up from $38.8 million at the end of the previous quarter, with no debt on its balance sheet [13] Fiscal Year Guidance - AngioDynamics updated its fiscal 2026 sales guidance to a range of $312-$314 million, up from the previous guidance of $308-$313 million [14] - The company anticipates Med Tech revenue growth of 14-16% and flat to 1% growth for Med Device revenues [15] - Adjusted loss per share is projected to be between 33 cents and 23 cents, with the Zacks Consensus Estimate at a loss of 28 cents per share [16] Overall Assessment - AngioDynamics demonstrated strong execution in the second quarter, with revenue growth driven by the higher-margin Med Tech portfolio, which now accounts for 45% of total revenue [17] - Auryon continues to be a significant growth driver, achieving its 18th consecutive quarter of double-digit growth [18] - The Mechanical Thrombectomy segment showed mid-single-digit growth, with regulatory advancements expected to enhance adoption and clinical use [19]

Core Insights - Intuitive Surgical (ISRG) stock has increased by 32.4% over the past three months, currently trading at $592.85, just 3.8% below its all-time high of $616 reached in February 2025, reflecting strong investor confidence following robust third-quarter earnings [1][19] Financial Performance - ISRG has outperformed peers like Medtronic (MDT) and PROCEPT BioRobotics (PRCT) in the past three months, with MDT gaining 2.5% and PRCT declining by 0.1% [2] - Total worldwide procedures grew by 20% year over year, driven by a 19% increase in da Vinci procedures and a 52% increase in Ion procedures [2][7] Growth Drivers - Procedure growth is a key component of Intuitive Surgical's long-term value creation, with strong performance noted across various geographies and specialties, including U.S. benign general surgery and international growth in general surgery, gynecology, colorectal, and thoracic procedures [3] - Average system utilization increased by 4% for da Vinci multiport, 35% for SP, and 14% for Ion, indicating rising throughput within the installed base [4] Product Development - The launch of da Vinci 5 is a significant catalyst for revenue growth, with 240 systems placed in Q3, bringing the global installed base to 929 systems [5][7] - Approximately 85% of ISRG's revenues come from recurring sales, supported by features and upgrades of da Vinci 5 [7][9] Competitive Landscape - Rising competition in surgical robotics includes Medtronic's Hugo platform and Procept BioRobotics' AI-powered HYDROS system, which could impact Intuitive Surgical's market dominance [14][16] Future Outlook - Estimates for Intuitive Surgical's 2025 earnings have increased by 8.5% to $8.65 per share, indicating bullish sentiment [17] - Sustained procedure growth, rising utilization, and accelerating da Vinci 5 adoption position the company for durable growth into 2026 [20]

Philadelphia, Pennsylvania--(Newsfile Corp. - January 7, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) ("Integer" or the "Company") on behalf of investors who purchased or otherwise acquired Integer securities during the period of July 25, 2024 through October 22, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased Integer securities during the Class Period may, no l ...

With a market cap of $11.2 billion, Align Technology, Inc. (ALGN) develops and provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services to patients and dental professionals worldwide. The company operates through two main segments: Clear Aligners, offering a range of Invisalign products for children, teens, and adults, and Imaging Systems & CAD/CAM Services, providing digital scanning, design software, and orthodontic workflow solutions. The Tempe, Arizona-based com ...

Core Insights - The article emphasizes the importance of efficiency levels in assessing a company's potential for profit generation, with a high efficiency level correlating positively with price performance [1] Efficiency Ratios - The article identifies key efficiency ratios for stock selection, including Receivables Turnover, Asset Utilization, Inventory Turnover, and Operating Margin, which help gauge a company's ability to manage credit, assets, inventory, and operating expenses effectively [2][3][4][5] - A favorable Zacks Rank (1 Strong Buy) is also included as a criterion to enhance the profitability of the stock screening process [6] Stock Screening Results - The screening process narrowed down over 7,906 stocks to 16, highlighting five companies that excel in efficiency ratios compared to industry averages [7] - The top five stocks identified are: - **United Natural Foods (UNFI)**: A leading distributor with a 52.10% average four-quarter earnings surprise [8][9] - **Northrim BanCorp (NRIM)**: A full-service commercial bank with a 19% average four-quarter earnings surprise [10] - **Lightspeed POS (LSPD)**: A commerce platform provider with a 17.9% average four-quarter earnings surprise [11] - **Ulta Beauty (ULTA)**: A prominent beauty retailer with a 15.7% average four-quarter earnings surprise [12] - **Electromed (ELMD)**: A manufacturer of airway clearance therapy products with a 13.6% average four-quarter earnings surprise [13]

Core Insights - A new retrospective analysis published in Diabetes Care indicates that users of the MiniMed™ 780G system can achieve American Diabetes Association (ADA) recommended goals for time-in-range (TIR) even on days when mealtime boluses are missed, with a reported TIR of 76.3% on such days when using SmartGuard™ technology with optimal settings [1][4][6] Group 1: Study Findings - The study analyzed real-world CareLink™ user data from 369,467 individuals using the MiniMed™ 780G insulin pump, focusing on 54,553 users who experienced at least 10 days without bolusing between January 2, 2020, and March 31, 2025 [4] - Users employing recommended optimal settings achieved a TIR of 76.3%, compared to 69.3% for those using non-recommended settings, with a mean sensor glucose of 149 mg/dL versus 160 mg/dL [6] - More than 61% of users with recommended optimal settings met all three ADA recommended glycemic targets on missed bolus days, compared to 36.6% of users with other settings [6] Group 2: Implications for Diabetes Management - The findings underscore the advanced capabilities of the MiniMed™ 780G system, which adjusts insulin delivery every five minutes based on sensor readings, providing support when boluses are missed or carbohydrates are underestimated [3][4] - The study highlights the importance of optimized settings in diabetes management, particularly for users who may occasionally miss boluses, thereby reducing the overall burden of diabetes care [2][4] Group 3: Company Overview - Medtronic Diabetes aims to make diabetes management more predictable through advanced technology, including next-generation sensors and intelligent dosing systems [8] - The company has been a pioneer in diabetes technology for over 40 years, focusing on customer experience and innovative solutions to improve health outcomes [9]